Shah Shailja C, Naymagon Steven, Cohen Benjamin L, Sands Bruce E, Dubinsky Marla C
The Dr Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, NY.
J Clin Gastroenterol. 2018 Apr;52(4):333-338. doi: 10.1097/MCG.0000000000000779.
Despite published clinical guidelines, substantive data underlying the approach to the management of hospitalized ulcerative colitis (UC) patients failing outpatient therapy are lacking. Variability in practice is therefore not uncommon and may impact clinical outcomes. The degree of variability, however, is not well-studied. Our aim was to evaluate variability in management of the hospitalized UC patient to inform future efforts targeting care optimization for this high-risk population.
An internet survey was distributed among inflammatory bowel disease providers, which included: (1) nonvignette-based questions assessing provider demographics, experience, and practice setting; (2) diagnostic and therapeutic practice patterns based on a vignette of a hospitalized UC patient. Descriptive and univariate analyses were performed.
Ninety-one percent of eligible individuals were included. Nearly 97% endorsed confidence in management of hospitalized UC patients. In general, 83% initiate intravenous corticosteroids (IVCS) as initial therapy, whereas 17% initiate infliximab (IFX) (+/-IVCS). At IVCS failure in the vignette, 74% initiated IFX, 15% increased IVCS dose, 7% initiated cyclosporine, and 4% chose colectomy. Of those choosing IFX, 65% chose 5 mg/kg as the initial dose, whereas the remainder chose 10 mg/kg. Twenty-eight percent gave an additional IFX 5 mg/kg and 7% gave an additional 10 mg/kg dose to the patient in the vignette not responding to 5 mg/kg.
Even among experienced inflammatory bowel disease providers, there is significant practice pattern variability in the management of hospitalized UC patients. Future efforts should target this variability. Adjunctively, prospective trials are needed to guide appropriate therapeutic algorithms, especially with respect to positioning and optimally dosing IFX in this population.
尽管已发布临床指南,但对于门诊治疗失败的住院溃疡性结肠炎(UC)患者的管理方法,相关实质性数据仍很缺乏。因此,实践中的差异并不罕见,且可能影响临床结果。然而,差异程度尚未得到充分研究。我们的目的是评估住院UC患者管理中的差异,为未来针对这一高危人群优化护理的工作提供参考。
在炎症性肠病医疗服务提供者中开展了一项网络调查,调查内容包括:(1)基于非病例的问题,评估医疗服务提供者的人口统计学特征、经验和执业环境;(2)基于一名住院UC患者病例的诊断和治疗实践模式。进行了描述性和单变量分析。
91%符合条件的个体参与了调查。近97%的人认可对住院UC患者的管理能力。总体而言,83%的人将静脉注射皮质类固醇(IVCS)作为初始治疗,而17%的人将英夫利昔单抗(IFX)(±IVCS)作为初始治疗。在病例中IVCS治疗失败时,74%的人开始使用IFX,15%的人增加IVCS剂量,7%的人开始使用环孢素,4%的人选择结肠切除术。在选择IFX的人中,65%选择5mg/kg作为初始剂量,其余人选择10mg/kg。在病例中,对于对5mg/kg无反应的患者,28%的人额外给予5mg/kg的IFX,7%的人额外给予10mg/kg的剂量。
即使在经验丰富的炎症性肠病医疗服务提供者中,住院UC患者的管理实践模式也存在显著差异。未来的工作应针对这种差异。此外,需要进行前瞻性试验以指导合适的治疗方案,特别是关于在该人群中IFX的使用时机和最佳剂量。